Profound Medical (PROF) Common Equity (2018 - 2026)

Profound Medical has reported Common Equity for 9 years, with the latest figure at $59.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 17.0% year-over-year to $59.4 million; the trailing twelve-month figure through Mar 2026 stood at $59.4 million (up 17.0% YoY), and the FY2025 full-year result was $66.4 million, up 9.95% from the prior year.
• Common Equity for Q1 2026 stood at $59.4 million, down from $66.4 million in the prior quarter.
• The five-year high for Common Equity was $66.4 million in Q4 2025, with the low at $30.7 million in Q3 2024.
• Average Common Equity over 5 years is $46.1 million, with a median of $45.5 million recorded in 2024.
• Year-over-year, Common Equity sank 40.64% in 2023 and surged 93.51% in 2024.
• Tracing PROF's Common Equity over 5 years: stood at $52.6 million in 2022, then slumped by 40.64% to $31.2 million in 2023, then surged by 93.51% to $60.4 million in 2024, then increased by 9.95% to $66.4 million in 2025, then fell by 10.55% to $59.4 million in 2026.
• The last three Common Equity figures came in at $59.4 million (Q1 2026), $66.4 million (Q4 2025), and $32.1 million (Q3 2025), per Business Quant data.

Peer Comparison